Eikon Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	68.4	67.11	55.81	58.48
Research & Development	270.05	247.32	204.54	207.26
Operating Expenses	338.45	314.43	260.34	265.74
Operating Income	-338.45	-314.43	-260.34	-265.74
Interest Expense	-0.84	-0.84	-0.03	-0.04
Interest & Investment Income	17.39	15.57	16.56	23.74
Other Non Operating Income (Expenses)	-0.06	-0.03	-0	0.04
EBT Excluding Unusual Items	-321.96	-299.73	-243.81	-242
Merger & Restructuring Charges	0.01	-3.29	-	-
Asset Writedown	-0.21	-21.23	-	-
Pretax Income	-322.16	-324.25	-243.81	-242
Net Income	-322.16	-324.25	-243.81	-242
Preferred Dividends & Other Adjustments	-	9.4	-	-
Net Income to Common	-322.16	-333.64	-243.81	-242
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	23	3	3	2
Shares Outstanding (Diluted)	23	3	3	2
Shares Change	-	14.85%	24.35%	-
EPS (Basic)	-13.72	-115.29	-96.76	-119.43
EPS (Diluted)	-13.72	-115.29	-96.76	-119.43
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-259.2	-235.26	-219.6	-219.36
Free Cash Flow Per Share	-11.04	-81.29	-87.16	-108.26
EBITDA	-317.23	-295.55	-245.34	-254.31
D&A For EBITDA	21.22	18.87	15.01	11.43
EBIT	-338.45	-314.43	-260.34	-265.74

SEC Filings: 10-K · 10-Q